1. Introduction {#j_med-2018-0025_s_001}
===============

Calciphylaxis is a serious systemic disorder of smaller arteries, arterioles and capillaries seen in 1% to 4% of patients with end-stage renal disease on hemodialysis and is usually associated with elevated calcium-phosphate product \[[@j_med-2018-0025_ref_001]\]. It is a clinical condition with mortality rate higher than 60% \[[@j_med-2018-0025_ref_002]\]. Penile calciphylaxis is rare because of its rich vascular network and the prognosis is also poor, with a reported overall mortality rate of 64% and mean time to death of 2.5 months \[[@j_med-2018-0025_ref_001],[@j_med-2018-0025_ref_003]\]. The benefit of penectomy is still under debate. Herein, we present a hemodialysis-dependent diabetic patient who presented with subacute distal penile dry gangrene due to penile calciphylaxis, and review the pertinent medical literature.

2. Case report {#j_med-2018-0025_s_002}
==============

A 43-year-old man presented with fever, chills and a purulent sternotomy wound. He had a history of end-stage renal disease for which he had been treated with hemodialysis for 6 years, poorly controlled type II diabetes mellitus, hypertension, and double vessel coronary artery disease. He had undergone coronary artery bypass graft surgery 2 months before this presentation, and received debridement for a sternotomy wound infection and pectoralis major myocutaneous flap rotation 1 month before this presentation. One month after admission, he presented with dry gangrene of the distal third of the penis, including the glans and part of the shaft for 7 days ([Figure 1](#j_med-2018-0025_fig_001){ref-type="fig"}). Dry gangrene was also present in both feet, the right ankle and thigh. Serum phosphate was 6.7 mg/dL (2.7-4.5 mg/dL), calcium was 9.8 mg/dL (8.9-10.3 mg/dL), calcium-phosphate product was 65.7 mg^2^/dl^2^ (20.6-52.5 mg^2^/dl^2^), albumin was 2.4g/dL (3.5-5.0 g/dL), HbA1c was 9.0%, and BMI was 24.8kg/m^2^. He did not take any anticoagulant medication, such as Warfarin. Computed tomography of his abdomen showed severe diffuse vascular calcifications, including in the branches of bilateral internal iliac arteries ([Figure 2](#j_med-2018-0025_fig_002){ref-type="fig"}). Due to penile pain and progression of necrosis of the distal penis, penectomy was performed. The intraoperative findings after penile degloving showed extensive ischemic damage, and the spongiosal and cavernosal tissues of the pendulous part of the penis showed no signs of vitality. After incision of the cavernous bodies, only blood clots were drained, and therefore we performed total penectomy and perineal urethrostomy. Plastic surgeon consultation suggested not to resect other extragenital gangrene due to patient's poor condition. The pathological report showed microcalcifications in the stroma and vascular wall consistent with calciphylaxis ([Figure 3](#j_med-2018-0025_fig_003){ref-type="fig"}). Dyspnea and conscious disturbances occurred after three days antibiotics usage for post-operative fever. His overall condition deteriorated and died of respiratory failure and sepsis 2 weeks later.

![Gangrenous penis.](med-13-158-g001){#j_med-2018-0025_fig_001}

![Internal pudendal (large arrow) and penile artery (small arrow) calcification seen on computed tomography.](med-13-158-g002){#j_med-2018-0025_fig_002}

![Calcifications in the vascular wall within the gangrenous penile shaft.](med-13-158-g003){#j_med-2018-0025_fig_003}
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3. Discussion {#j_med-2018-0025_s_003}
=============

Calciphylaxis is characterized by medial calcification and intimal fibrosis of medium and small arteries. Mottling of the skin and induration in a livedo reticularis pattern is a characteristic clinical presentation of calciphylaxis, which generally affects the distal extremities, buttocks, and thighs, and sometimes the penis. Penile calciphylaxis has an extremely poor prognosis, with a reported overall mortality rate of 64% and mean time to death of 2.5 months \[[@j_med-2018-0025_ref_003]\]. Cimmino et al. recommend penile biopsy is unnecessary for diagnosis of penile calciphylaxis \[[@j_med-2018-0025_ref_004]\].

A total of 50 cases of penile calciphylaxis have been reported in the English literature ([Table 1](#j_med-2018-0025_tab_001){ref-type="table"}) \[[@j_med-2018-0025_ref_002],[@j_med-2018-0025_ref_003],[@j_med-2018-0025_ref_004],[@j_med-2018-0025_ref_005],[@j_med-2018-0025_ref_006],[@j_med-2018-0025_ref_007],[@j_med-2018-0025_ref_008],[@j_med-2018-0025_ref_009],[@j_med-2018-0025_ref_010],[@j_med-2018-0025_ref_011],[@j_med-2018-0025_ref_012],[@j_med-2018-0025_ref_013],[@j_med-2018-0025_ref_014],[@j_med-2018-0025_ref_015],[@j_med-2018-0025_ref_016],[@j_med-2018-0025_ref_017],[@j_med-2018-0025_ref_018],[@j_med-2018-0025_ref_019],[@j_med-2018-0025_ref_020],[@j_med-2018-0025_ref_021],[@j_med-2018-0025_ref_022],[@j_med-2018-0025_ref_023],[@j_med-2018-0025_ref_024],[@j_med-2018-0025_ref_025],[@j_med-2018-0025_ref_026],[@j_med-2018-0025_ref_027],[@j_med-2018-0025_ref_028],[@j_med-2018-0025_ref_029],[@j_med-2018-0025_ref_030],[@j_med-2018-0025_ref_031],[@j_med-2018-0025_ref_032],[@j_med-2018-0025_ref_033],[@j_med-2018-0025_ref_034],[@j_med-2018-0025_ref_035],[@j_med-2018-0025_ref_036],[@j_med-2018-0025_ref_037],[@j_med-2018-0025_ref_038],[@j_med-2018-0025_ref_039],[@j_med-2018-0025_ref_040],[@j_med-2018-0025_ref_041]\]. The average age was 54.5 years (range 32 to 81). Including our case, all patients had end stage renal disease, 42 patients received hemodialysis, 7 patients received peritoneal dialysis and 2 patients were in the pre-dialysis stage. Forty-one patients had diabetes mellitus. Average calcium level was 9.2 mg/dl, average phosphate level was 8.0 mg/dl and average calcium-phosphate product was 72.8 mg^2^/dl^2^. The overall mortality rate was 56.5%. Three-month mortality rate was 47.8%. Mean time to death was 97 days and median time to death was a month. There was no correlation between mortality rate and age, diabetes mellitus, calcium level, phosphate level and calcium-phosphate product level.

###### 

Review of reported cases of penile calciphylaxis with end-stage renal disease.

  Authors                                        Age   Ca        P         CaP       PTH       extragenital gangrene   penectomy   parathyroidectomy                                         3-month prognosis
  ---------------------------------------------- ----- --------- --------- --------- --------- ----------------------- ----------- --------------------------------------------------------- -------------------
  MMH                                            43    9.8       6.7       65.7      no data   yes                     yes         no                                                        death
  Ivker RA\[[@j_med-2018-0025_ref_005]\]         43    9.2       5.6       51.5      375       yes                     no          yes                                                       alive
  Ivker RA\[[@j_med-2018-0025_ref_005]\]         58    7.9       6.4       50.6      89        yes                     yes         yes                                                       alive
  Melikoglu M\[[@j_med-2018-0025_ref_006]\]      48    7.4       11        81.4      no data   yes                     yes         no                                                        death
  Wood JC\[[@j_med-2018-0025_ref_007]\]          56    8.9       9         80.1      1280      yes                     yes         yes                                                       alive
  Jhaveri FM\[[@j_med-2018-0025_ref_008]\]       62    9.3       9.5       88.4      74        yes                     no          no                                                        death
  Jhaveri FM\[[@j_med-2018-0025_ref_008]\]       44    10.5      7.6       79.8      1450      yes                     no          yes                                                       alive
  Jhaveri FM\[[@j_med-2018-0025_ref_008]\]       44    10        10.2      102       405       yes                     no          yes                                                       loss
  Jhaveri FM\[[@j_med-2018-0025_ref_008]\]       41    10.6      7.1       75.3      746       yes                     no          no                                                        death
  Jhaveri FM\[[@j_med-2018-0025_ref_008]\]       59    10.3      7.4       76.2      89        yes                     no          yes                                                       death
  Siami GA\[[@j_med-2018-0025_ref_009]\]         44    7.9       8.6       67.9      no data   yes                     yes         no                                                        death
  Boccaletti VP\[[@j_med-2018-0025_ref_010]\]    72    10.5      7.8       91.9      881       no                      no          no                                                        death
  Rich A\[[@j_med-2018-0025_ref_011]\]           34    no data   no data   no data   no data   yes                     yes         no                                                        death
  Jacobsohn HA\[[@j_med-2018-0025_ref_012]\]     60    9.7       9         87        430       yes                     yes         no                                                        death
  Karpman E\[[@j_med-2018-0025_ref_003]\]        59    7.9       9.6       75.8      379       yes                     yes         no                                                        death
  Barthelmes L\[[@j_med-2018-0025_ref_013]\]     48    no data   no data   no data   no data   no                      yes         no                                                        death
  Oikawa S\[[@j_med-2018-0025_ref_014]\]         32    no data   no data   no data   63        yes                     no          yes[^\*^](#j_med-2018-0025_fn_001){ref-type="table-fn"}   death
  Rifkin BS\[[@j_med-2018-0025_ref_015]\]        61    no data   no data   no data   no data   yes                     no data     no data                                                   loss
  Woods M\[[@j_med-2018-0025_ref_016]\]          35    8.4       7.4       62.2      38        no                      yes         no                                                        death
  Halachmi S\[[@j_med-2018-0025_ref_017]\]       57    8.5       8.5       76.5      375       yes                     no          no                                                        death
  Agarwal MM\[[@j_med-2018-0025_ref_018]\]       52    8.5       7.5       63.8      no data   yes                     no          no                                                        death
  Sorensen MD\[[@j_med-2018-0025_ref_019]\]      65    8.5       no data   no data   121       no                      yes         no                                                        alive
  Ohta A\[[@j_med-2018-0025_ref_020]\]           41    9.8       5.2       51        18        yes                     yes         no                                                        alive
  Rizvi T\[[@j_med-2018-0025_ref_021]\]          72    7.4       7.3       54        315       no                      no          no                                                        alive
  Bhatty TA\[[@j_med-2018-0025_ref_022]\]        39    no data   7.1       no data   344.7     yes                     no          no                                                        alive
  Sandhu G\[[@j_med-2018-0025_ref_023]\]         58    10.2      10.3      105.1     82        no                      no          no                                                        alive
  Bappa A\[[@j_med-2018-0025_ref_024]\]          72    9.6       7.3       70.1      315.2     yes                     no          no                                                        loss
  Shah MA\[[@j_med-2018-0025_ref_025]\]          72    7.9       6.6       52.1      164       yes                     no          no                                                        death
  Prematilleke I\[[@j_med-2018-0025_ref_026]\]   66    10.4      5.9       61.4      30.8      no                      yes         no                                                        death
  Prematilleke I\[[@j_med-2018-0025_ref_026]\]   38    9.9       7.7       76.2      48        no                      yes         no                                                        alive
  O'Neil B\[[@j_med-2018-0025_ref_027]\]         72    8.9       5         44.5      1462      no                      yes         yes                                                       alive
  O'Neil B\[[@j_med-2018-0025_ref_027]\]         59    no data   no data   no data   816       yes                     yes         yes                                                       alive
  O'Neil B\[[@j_med-2018-0025_ref_027]\]         64    8         8.1       64.8      516       no                      yes         yes                                                       alive
  Akai A\[[@j_med-2018-0025_ref_028]\]           36    no data   no data   56        no data   yes                     no          no                                                        alive
  Kumar V\[[@j_med-2018-0025_ref_029]\]          73    8.8       11.8      103.8     633       no                      no          no                                                        alive
  Barbera V\[[@j_med-2018-0025_ref_030]\]        50    12.8      8.6       110.1     615       no                      yes         no                                                        alive
  Yecies T\[[@j_med-2018-0025_ref_031]\]         33    no data   no data   no data   no data   no                      yes         no                                                        alive
  Cimmino CB\[[@j_med-2018-0025_ref_004]\]       62    9         8.4       75.6      no data   no                      no          no                                                        alive
  Cimmino CB\[[@j_med-2018-0025_ref_004]\]       38    8.7       no data   no data   no data   yes                     no          no                                                        loss
  Cimmino CB\[[@j_med-2018-0025_ref_004]\]       49    7.4       9.6       71        799.8     no                      no          no                                                        loss
  Haider I\[[@j_med-2018-0025_ref_032]\]         61    no data   no data   no data   260       yes                     no          no                                                        death
  Morrison M\[[@j_med-2018-0025_ref_033]\]       60    no data   no data   no data   no data   yes                     no          no                                                        alive
  Hanna RM\[[@j_med-2018-0025_ref_034]\]         64    9         13.5      121.5     612       yes                     yes         no                                                        alive
  Sarkis E\[[@j_med-2018-0025_ref_002]\]         54    no data   no data   no data   94        yes                     no          no                                                        death
  Malthouse T\[[@j_med-2018-0025_ref_035]\]      61    9.1       8.4       75.9      155       yes                     no          no                                                        death
  Shiraki T\[[@j_med-2018-0025_ref_036]\]        76    no data   no data   42        127       yes                     no          no                                                        alive
  Endly D\[[@j_med-2018-0025_ref_037]\]          58    9         4.1       39.8      410       yes                     no          no                                                        death
  Bashir SO\[[@j_med-2018-0025_ref_038]\]        46    9.5       7.4       70.3      600       no                      no          yes                                                       alive
  Maselli G\[[@j_med-2018-0025_ref_039]\]        64    no data   no data   no data   no data   no                      no          no                                                        alive
  Campbell RA\[[@j_med-2018-0025_ref_040]\]      46    10.7      6         64.2      1096      no                      yes         no                                                        alive
  Olaoye OA\[[@j_med-2018-0025_ref_041]\]        81    9.8       8.4       82.3      1131      no                      no          no                                                        death

Ca, calcium; P, phosphate; CaP, calcium-phosphate product; PTH, parathyroid hormone

Calciphylaxis was developed after parathyroidectomy

Parathyroid hormone level was reported in 38 patients and average parathyroid hormone level was 458.9 pg/ml. Secondary hyperparathyroidism was found in 33 patients. One patient underwent parathyroidectomy before and 10 patients underwent parathyroidectomy after calciphylaxis developed. The 3-month mortality rates were 33.3% and 60% in patients undergoing parathyroidectomy after calciphylaxis and patients without parathyroidectomy, respectively (P=0.18). Mortality rate was not correlated with parathyroid hormone level and parathyroidectomy. This finding was different from that reported by Karpman et al., who suggested that parathyroidectomy may improve survival \[[@j_med-2018-0025_ref_003]\]. The possible reason for the difference was that they included patients without documented parathyroid hormone level in their statistics.

Extragenital gangrene was noted in 32 patients. The 3-month mortality rate was higher in patients with extragenital gangrene than in those without extragenital gangrene (60.7% vs. 27.8%, p=0.03). Extragenital gangrene involves more blood vessels and may result in worse prognosis.

Twenty-one patients received partial or total penectomy. The mortality rates were 42.9% and 52% in patients undergoing partial or total penectomy and patients who received local debridement and wound care, respectively (P=0.54). Karpman et al. also reported no statistically significant difference in survival between patients treated with penectomy and those treated with local debridement and wound care \[[@j_med-2018-0025_ref_003]\]. Since penectomy showed no survival benefit, we suggest that penectomy should be considered in the presence of severe pain refractory to analgesics or uncontrolled infection.

Akai A et al. reported a case of penile calciphylaxis who underwent femoral artery to deep dorsal penile vein bypass \[[@j_med-2018-0025_ref_028]\]. After revascularization surgery, pain subsided and the wound healed. Shiraki T et al. reported a case of penile calciphylaxis successfully treated with internal iliac artery balloon-expandable bare metal stent implantation \[[@j_med-2018-0025_ref_028]\]. Two cases were treated with hyperbaric oxygen therapy but both of them died within a month \[[@j_med-2018-0025_ref_012],[@j_med-2018-0025_ref_014]\].

Three cases were treated with sodium thiosulfate, and 2 patients survived \[[@j_med-2018-0025_ref_002],[@j_med-2018-0025_ref_023],[@j_med-2018-0025_ref_033]\]. The possible mechanism of sodium thiosulfate is chelation of calcium ions, dissolution of insoluble calcium deposits and restoration of endothelium \[[@j_med-2018-0025_ref_002]\]. In a retrospective study of 27 patients with calciphylaxis in other locations, 52% resolved with sodium thiosulfate administration \[[@j_med-2018-0025_ref_002]\].

Penile calciphylaxis is a rare disease with poor prognosis because calciphylaxis involves smaller arteries, arterioles and capillaries systemically. Unlike other penile gangrene, such as Fournier's gangrene, the benefit of aggressive surgical therapy is controversial. Patients with extragenital gangrene have higher rates of mortality. Due to its rarity, there is no consensus regarding the treatment of this disease. Conservative treatment, sodium thiosulfate, hyperbaric oxygen, internal iliac artery stent, revascularization surgery, penectomy and parathyroidectomy have all been described. Literature review showed that penectomy and parathyroidectomy had no significant survival benefit. However, since there is no definite curative treatment, physicians may attempt combining different treatment modalities.
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